Key result
Prolonged pretreatment of HeLa cells with CVB3-specific phosphorothioate oligodeoxynucleotides inhibited viral replication, though efficacy was likely limited by low cellular uptake.
Why the study?
Do CVB3-specific phosphorothioate oligodeoxynucleotides inhibit CVB3 replication in HeLa cells?
Do CVB3-specific phosphorothioate oligodeoxynucleotides inhibit CVB3 replication in HeLa cells?
CVB3-specific PS-ODNs require prolonged pretreatment to inhibit viral replication in vitro, likely due to low cellular uptake.
Answers are grounded in this paper and cite their sources.
Uptake barriers limit near-term antiviral utility; leaves open optimized PS-ODNs for CVB3 after delivery improvements.
The antiviral activity of PS-ODNs, complementary to different regions of the CVB3 genome, was investigated under in vitro conditions. Inhibition of CVB3 replication was detected only after prolonged pretreatment of HeLa cells with antiviral active PS-ODNs, but not when virus and PS-ODN were applicated simultaneously. Results from flow cytometric analysis indicate that a low cellular uptake of anti-CVB3 oligonucleotides into HeLa cells might be a reason for their moderate antiviral activity.
No takes yet. Share an insight, caveat, or question.
Schmidtke et al. (1998) studied Coxsackievirus B3 (CVB3) infection. Coxsackievirus B3 (CVB3)-specific phosphorothioate oligodeoxynucleotides (PS-ODNs) vs. Simultaneous application of virus and PS-ODN was evaluated on Inhibition of CVB3 replication. Prolonged pretreatment of HeLa cells with CVB3-specific phosphorothioate oligodeoxynucleotides inhibited viral replication, though efficacy was likely limited by low cellular uptake.
Synapse has enriched 10 related papers. Consider them for comparative context: